Projects overview

Sort by


Toggle all information

EBOVAC3 | Bringing a prophylactic Ebola vaccine to licensure

01-06-2018

-

30-09-2024

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2015-08-single-stage
IMI2-2015-08-01 Ebola and other filoviral haemorrhagic fevers (Ebola+) programme: future outbreaks

RHAPSODY | Assessing risk and progression of prediabetes and type 2 diabetes to enable disease modification - Sofia ref.: 115881

01-04-2016

-

30-09-2021

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2015-03-two-stage
IMI2-2015-03-02 Assessing Risk and Progression of Prediabetes and Type 2 Diabetes to Enable Disease Modification

ROADMAP | Real world Outcomes across the AD spectrum for better care: Multimodal data Access Platform - Sofia ref.: 116020

01-11-2016

-

31-10-2018

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2015-06-two-stage
IMI2-2015-06-03 Real World Outcomes Across the AD Spectrum (ROADS) to Better Care

MACUSTAR | Develop and validate appropriate and acceptable outcome measures in intermediate age-related macular degeneration for future interventional clinical trials - Sofia ref.: 116076

01-09-2017

-

31-05-2024

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2015-07-two-stage
IMI2-2015-07-04 DRY AGE-RELATED MACULAR DEGENERATION: DEVELOPMENT OF NOVEL CLINICAL ENDPOINTS FOR CLINICAL TRIALS WITH A REGULATORY AND PATIENT ACCESS INTENTION

BIGPICTURE | Central Repository for Digital Pathology

01-02-2021

-

31-01-2027

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2019-18-two-stage
IMI2-2019-18-01 Central repository of digital pathology slides to support the development of artificial intelligence tools

PD-MitoQUANT | PD-MitoQUANT – A quantitative approach towards the characterisation of mitochondrial dysfunction in Parkinson's disease

01-02-2019

-

31-07-2022

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2017-13-two-stage
IMI2-2017-13-04 Mitochondrial Dysfunction in Neurodegeneration

ERA4TB | EUROPEAN REGIMEN ACCELERATOR FOR TUBERCULOSIS

01-01-2020

-

31-12-2025

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2018-15-two-stage
IMI2-2018-15-08 AMR Accelerator programme Pillar B: Tuberculosis drug development network to accelerate and validate scientific discoveries and advance the R&D pipeline of new and innovative agents to address the global tuberculosis epidemic

ITCC-P4 | ITCC Pediatric Preclinical POC Platform – Sofia ref.: 116064

01-01-2017

-

31-12-2023

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2015-07-two-stage
IMI2-2015-07-05 A COMPREHENSIVE ‘PAEDIATRIC PRECLINICAL POC PLATFORM’ TO ENABLE CLINICAL MOLECULE DEVELOPMENT FOR CHILDREN WITH CANCER

PIONEER | Prostate Cancer DIagnOsis and TreatmeNt Enhancement through the Power of Big Data in EuRope

01-05-2018

-

31-10-2023

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2016-10-two-stage
IMI2-2016-10-02 How Big Data could support better diagnosis and treatment outcomes for Prostate Cancer

PharmaLedger | PharmaLedger

01-01-2020

-

31-12-2022

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2018-15-two-stage
IMI2-2018-15-02 Blockchain Enabled Healthcare

SISAQOL-IMI | Establishing international standards in the analysis of patient reported outcomes and health-related quality of life data in cancer clinical trials

01-01-2021

-

31-12-2024

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2019-18-two-stage
IMI2-2019-18-04 Establishing international standards in the analysis of patient reported outcomes and health-related quality of life data in cancer clinical trials

MOBILISE-D | Connecting digital mobility assessment to clinical outcomes for regulatory and clinical endorsement

01-04-2019

-

30-06-2024

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2017-13-two-stage
IMI2-2017-13-07 Linking digital assessment of mobility to clinical endpoints to support regulatory acceptance and clinical practice

HARMONY | Healthcare Alliance for Resourceful Medicines Offensive against Neoplasms in HematologY - Sofia ref.: 116026

01-01-2017

-

30-06-2023

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2015-06-two-stage
IMI2-2015-06-04 Development of an outcomes-focused data platform to empower policy makers and clinicians to optimize care for patients with hematologic malignancies

ConcePTION | Building an ecosystem for better monitoring and communicating of medication safety in pregnancy and breastfeeding: validated and regulatory endorsed workflows for fast, optimised evidence generation

01-04-2019

-

31-12-2024

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2017-13-two-stage
IMI2-2017-13-09 ConcePTION – Continuum of Evidence from Pregnancy Exposures, Reproductive Toxicology and Breastfeeding to Improve Outcomes Now

PREMIER | Prioritisation and Risk Evaluation of Medicines in the EnviRonment

01-09-2020

-

31-08-2026

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2019-17-two-stage
IMI2-2019-17-03 Intelligent prediction and identification of environmental risks posed by human medicinal products

EHDEN | European Health Data and Evidence Network

01-11-2018

-

31-10-2024

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2017-12-two-stage
IMI2-2017-12-04 European Health Data Network (EHDN)

IMPRiND | Inhibiting Misfolded protein PRopagation in Neurodegenerative Diseases - Sofia ref.: 116060

01-03-2017

-

28-02-2022

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2015-07-two-stage
IMI2-2015-07-02 IDENTIFICATION OF DRUGGABLE TARGETS MODULATING MISFOLDED PROTEINS IN ALZHEIMER’S AND PARKINSON’S DISEASES

FAIRplus | FAIRplus

01-01-2019

-

31-12-2022

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2017-12-two-stage
IMI2-2017-12-02 FAIRification of IMI and EFPIA data

BigData Heart | Big Data 4 Better Hearts - Sofia ref.: 116074

01-03-2017

-

28-02-2023

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2015-07-two-stage
IMI2-2015-07-07 INCREASE ACCESS AND USE OF HIGH QUALITY DATA TO IMPROVE CLINICAL OUTCOMES IN HEART FAILURE (HF), ATRIAL FIBRILLATION (AF), AND ACUTE CORONARY SYNDROME (ACS) PATIENTS
Powered by Chris Decubber BV